Update (June 26, 2026): Diabetic Remission in Cats — 2026 AAHA Guidelines Framework, Incidence, and Predictors

Bottom line.

• The 2026 AAHA Diabetes Management Guidelines for Cats define diabetic remission as euglycemia maintained for >4 weeks without exogenous insulin or oral hypoglycemic agents; approximately 25% of cats achieve remission in the first 2-3 months following diagnosis, with a majority achieving remission within 6 months; the task force supports using an average remission rate of approximately 30% in the United States.
• Diabetic remission is almost exclusively a feline phenomenon; it relies on reversal of insulin resistance and glucose toxicity with recovery of beta-cell function; cats with reversible causes of IR (obesity, recent glucocorticoid administration) are more likely to achieve remission.
• Cats receiving exogenous insulin that undergo unrecognised remission are vulnerable to life-threatening insulin-induced hypoglycemia; remission is signalled by progressive decrease in insulin requirements, urine glucose negativity for more than 48 hours, or serum fructosamine at or below the reference range.
• This is a clinician-facing evidence summary. It is not a dosing protocol; confirm regimen, monitoring and contraindications against current product labeling and a veterinary formulary.

Update context

Section 9 of the 2026 AAHA Diabetes Management Guidelines for Cats (published April 26, 2026) provides the current framework for understanding and monitoring diabetic remission in cats. This article summarises the key evidence and guideline recommendations from that section.

Managing a diabetic cat working toward remission?

Get an instant cited answer -- no signup needed for your first question. Voyage Clinical Desk brings species-specific monitoring plans and peer-reviewed evidence to the case in front of you.

Try Voyage Clinical Desk

What the evidence shows

Definition and mechanism

The 2026 AAHA guidelines define diabetic remission as euglycemia maintained for more than 4 weeks without exogenous insulin or oral hypoglycemic agents. This reflects recovery of beta-cell function that relies on reversal of insulin resistance and glucose toxicity. However, diabetic cats undergoing remission are not cured: pancreatic insulin reserve is permanently limited and relapse is common.

Diabetic remission is almost exclusively a feline phenomenon -- a fact that supports the insulin-resistant pathophysiological model for feline DM and distinguishes it fundamentally from canine DM, in which permanent beta-cell destruction makes remission rare.

Incidence and timing of remission

The 2026 guidelines report:

• Approximately 25% of cats achieving remission did so in the 2-3 months following diagnosis
• A majority of cats achieved remission within 6 months
• Reported incidences vary by patient characteristics and management strategies
• The task force supports using an average remission rate of approximately 30% in the United States

These figures are drawn from observational cohort studies of diabetic cats managed with insulin and low-carbohydrate diets.

Predictors and risk factors for remission

The 2026 guidelines identify the following as associated with higher remission rates:

• Reversible causes of insulin resistance: Obesity (with successful weight management), recent glucocorticoid or progestogen administration (with withdrawal of the offending drug). These cats are also particularly vulnerable to hypoglycemia if treated with insulin.
• Active comorbidity management: Promptly address causes of IR such as dental disease rather than postponing until blood glucose is adequately regulated.
• Diet: Canned high-protein (low-carbohydrate) diets may support remission by mitigating sarcopenia and boosting secretion of GLP-1, an incretin with trophic effects on beta cells.
• History of DKA or peripheral neuropathy: A 2024 study reported similar rates of remission in cats with historic DKA (9.8%) and those with neuropathy (8.5%) at diagnosis -- lower rates but remission is still possible.
• Hypersomatotropism (acromegaly): Not expected to undergo remission without definitive treatment for the underlying condition.

Monitoring for remission onset

The 2026 guidelines state that remission onset is readily apparent if BG is routinely monitored, but may be overlooked in unmonitored cats until obvious signs of hypoglycemia appear. Indicators that support remission include:

• Progressive decrease in insulin requirements or evidence of hypoglycemia in insulin-treated cats
• Zero glucosuria for more than 48 hours (less sensitive; caveats apply for SGLT2-treated cats which have drug-induced glucosuria)
• Serum fructosamine at or below the reference range

For cats receiving an SGLT2 inhibitor, the drug must be withheld to identify remission. The 2026 guidelines suggest checking for remission after at least 90 days of SGLT2 inhibitor therapy by monitoring BG with a CGM or 1-2 glucometer checks per day for at least a week; BG persistently greater than 250 mg/dL with ongoing clinical signs of DM indicates need for continued treatment.

Risk of unrecognised remission -- hypoglycemia hazard

The 2026 guidelines highlight that cats receiving exogenous insulin that undergo unrecognised remission are vulnerable to life-threatening insulin-induced hypoglycemia. This makes owner education about the signs of hypoglycemia and regular glucose monitoring essential for any insulin-treated diabetic cat.

Relapse rates and second remission

Achieving a second remission is less common than the first, with reported rates ranging between 0-22%. Cats that undergo remission but subsequently relapse often lose enough beta cells to ultimately require exogenous insulin permanently.

Maintenance after remission

The 2026 guidelines recommend diligent weight management and continued use of a canned low-carbohydrate diet for all cats in remission. Physical examination with monitoring of clinical signs, weight, and appropriate laboratory evaluation every 6 months is recommended to allow early detection of possible diabetic relapse. Long-term use of an SGLT2 inhibitor to prevent relapse is acknowledged as a possibility but described as extra-label use requiring more research.

How this fits clinical practice

The 2026 AAHA framework for diabetic remission in cats underscores three practical priorities: (1) identifying and addressing reversible causes of insulin resistance at diagnosis, (2) maintaining effective glycemic control to allow beta-cell recovery, and (3) ongoing monitoring to detect remission early before hypoglycemia occurs. Clinicians should communicate remission probability and relapse risk to owners, and ensure owners are educated about hypoglycemia risk during the transition off insulin. Confirm monitoring thresholds and drug regimens against current product labeling and the full 2026 AAHA guidelines.

Voyage Clinical Desk

From clinical question to SOAP draft -- cited differentials, live dose calculators, owner handouts. First answer free, no signup.

Open Voyage Clinical Desk

References

1. American Animal Hospital Association. 2026. 2026 AAHA Diabetes Management Guidelines for Cats -- Section 9: Diabetic Remission. Published April 26, 2026. https://www.aaha.org/resources/2026-aaha-diabetes-management-guidelines-for-cats/section-9-diabetic-remission/
2. American Animal Hospital Association. 2026. 2026 AAHA Diabetes Management Guidelines for Cats -- Section 1: Overview of Diabetes Mellitus in Cats. https://www.aaha.org/resources/2026-aaha-diabetes-management-guidelines-for-cats/section-1-overview-of-diabetes-mellitus-in-cats/

Changelog

• 2026-06-26: First published.